NCT01160055

Brief Summary

The purpose of this epidemiological study is to identify and characterize the bacteria causing Acute Otitis Media episodes in children aged \>= 3 months to \< 5 years in Egypt.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2012

Shorter than P25 for all trials

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 1, 2010

Completed
11 days until next milestone

First Posted

Study publicly available on registry

July 12, 2010

Completed
2.2 years until next milestone

Study Start

First participant enrolled

October 1, 2012

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

April 13, 2015

Status Verified

April 1, 2015

Enrollment Period

8 months

First QC Date

July 1, 2010

Last Update Submit

April 9, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Occurrence of bacterial pathogens isolated from middle ear fluid samples.

    12 Months

Secondary Outcomes (6)

  • Occurrence of bacterial serotypes.

    12 Months

  • Antimicrobial susceptibility of bacteria isolated from middle ear fluid samples, as assessed by standard microbiological techniques.

    12 Months

  • Occurrence of treatment failure of acute otitis media and of recurrent acute otitis media.

    12 Months

  • Occurrence of spontaneous otorrhoea.

    12 Months

  • Occurrence of bacteria in acute otitis media cases with treatment failure and in new Acute Otitis Media cases without treatment therapy.

    12 Months

  • +1 more secondary outcomes

Study Arms (2)

Cohort A

Subjects with a new episode of Acute Otitis Media (\<3 days of onset) who have not yet received antibiotic therapy for the episode.

Procedure: Middle ear fluid and urine.

Cohort B

Subjects who have had a diagnosis of Acute Otitis Media within 2-3 days prior to study enrolment and received antibiotic therapy, but remain symptomatic.

Procedure: Middle ear fluid and urine.

Interventions

Middle ear fluid and urine collection.

Cohort ACohort B

Eligibility Criteria

Age3 Months - 5 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Children aged \>= 3 months to \< 5 years visiting ear, nose and throat specialists for the treatment of acute otitis media.

You may qualify if:

  • Age: \>= 3 months and \< 5 years at the time of enrolment. The subject becomes ineligible on the fifth birthday.
  • Signs, symptoms, and conditions:
  • One of the functional or general signs of otalgia, conjunctivitis, fever AND EITHER
  • Paradise's criteria, OR
  • Spontaneous otorrhoea of less than 1 day.
  • Onset of signs and symptoms of acute otitis media within 3 days prior to diagnosis of acute otitis media by a physician. To be included as treatment failure, subjects must have then received antibiotic treatment from the physician, but remain symptomatic 2-3 days after initiation of treatment.
  • Written informed consent obtained from parent(s) or Legally Acceptable Representative prior to study start.

You may not qualify if:

  • Hospitalised during the diagnosis of acute otitis media or during treatment,
  • Otitis externa, or otitis media with effusion,
  • Presence of a transtympanic aerator,
  • Systemic antibiotic treatment received for a disease other than acute otitis media in the 3 days prior to enrolment,
  • Receiving antimicrobial prophylaxis for recurrent acute otitis media,
  • Provision of antibiotic by the ear nose and throat specialist at the enrolment visit, prior to the sampling of the middle ear fluid by tympanocentesis or spontaneous otorrhoea,
  • Patients on antibiotics for acute otitis media who are clinically improving.
  • Child in care.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

Middle ear fluid, Urine.

MeSH Terms

Conditions

Streptococcal Infections

Interventions

Urination

Condition Hierarchy (Ancestors)

Gram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections

Intervention Hierarchy (Ancestors)

Urinary Tract Physiological PhenomenaReproductive and Urinary Physiological Phenomena

Study Officials

  • GSK Clinical Trials

    GlaxoSmithKline

    STUDY DIRECTOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 1, 2010

First Posted

July 12, 2010

Study Start

October 1, 2012

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

April 13, 2015

Record last verified: 2015-04